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The Institute ofMedicine of theUSNational Academy of Sciences issued amajor report in 2012
that provides important guidance for the proteomics community for credible and transparent
development of all kinds of omics-based diagnostic and prognostic tests. The key elements
are summarized here to provide a compass that can guide the studies emerging from many
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1 Introduction
Molecular signatures are becoming useful biomarkers for di-
agnosis, prognosis, choice of therapy, response to therapy,
and recurrence of disease. Proteomics, especially with the
new SRM-targeted proteomics approaches, is in the center of
this work. In fact, integration of multiple omics approaches
(genomics, epigenomics, transcriptomics, miR-omics, pro-
teomics, metabolomics) is likely to be the most compre-
hensive and productive route to “personalized” or “precision
medicine” [1]. Integration is a key feature of our scheme for
linking fromgenome to phenome, or phenome to genome [2];
see Fig. 1.
Omics research generates complex high-dimensional
data. Often there are measurements of far more variables
per sample than the total number of biological samples used
to generate the dataset. These data require a computational
model or algorithm to distinguish a health-related character-
istic of clinical significance in one group (patients) compared
with another (controls/normal) or in two different subgroups
of patients with the same general diagnosis.
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As emphasized in the 2012 report “Evolution of Trans-
lational Omics: Lessons Learned and Path Forward,” [3]
high-dimensional data are prone to “overfitting.” This phe-
nomenon refers to results that cannot be replicated in an
independent set of samples, a huge problem in the literature
of disease biomarkers. A computational model created in the
discovery phase of research on a certain set of samples may
be less accurate or useless when applied to another set of
samples. A standardized, carefully executed series of studies
is required to achieve a validated clinical test suitable for eval-
uation in a clinical setting, especially for making decisions to
improve outcomes from care of the patient.
Omics-based tests differ fromcommon single analyte tests
inmany respects. Unlike a specific assay for LDL receptor or a
hemoglobin variant or a particular enzyme, where a sound bi-
ological rationale links the assay to the disease process, global
analysis of nearly all the genes or hundreds or thousands of
proteins in “unbiased discovery studies” rests on statistical
and informatics methods for interpretation.
2 The importance of transparent, fully
annotated data sharing
The complexity of omics research puts a premium on data
provenance and sharing of both data and the details of the
computationalmodel. Proteomics researchers have lagged far
behind genomics researchers in promptly committing their
data and metadata to publicly accessible data repositories.
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Figure 1. Scheme showingmul-
tidimensional omics analyses,
physiological and clinical mea-
sures, and environmental, be-
havioral, and social influences
on health and disease, linking
genome and phenome (pheno-
types). Source: [2] p.51.
Without access to the data and classifier for independent
confirmation, it is not feasible for others to replicate and
verify the results.
The HUPO Human Proteome Project (www.thehpp.org)
has committed that the participating investigator teams will
submit their datasets through the new ProteomeXchange
mechanism (Vizcaı´no et al., Nat. Biotechnol., in press) into
the curated PRIDE repository at the European Bioinformat-
ics Institute and into Peptide Atlas at the Institute for Sys-
tems Biology for standardized reanalysis using the TransPro-
teomicPipeline. GPMdb also combines and reanalyzes
datasets, using X!Tandem. Targeted MRM/SRM proteomics
data can now be submitted to SRM Atlas using PASSEL [4].
3 The IOM scheme for development
of omics-based tests
The development of omics-based multianalyte tests has been
much slower than expected. A major reason is the lack of a
widely agreed-upon process for translation of omics discover-
ies into clinical omics-based tests. Detailed case studies of six
clinically useful multianalyte tests are presented in Appendix
A of the 2012 IOM report [3]: Oncotype DX andMammaPrint
to guide decisions on whether patients treated for breast can-
cer are at sufficient risk of recurrence andmetastases that they
should have toxic adjuvant chemotherapy to reduce the risk
of metastases; Tissue of Origin for cancers of unknown site
of origin; OVA1, a set of five abundant proteins, to guide the
choice of a gynecologic surgeon instead of a general surgeon
for women with known pelvic mass that might be ovarian
cancer or other, often benign, tumor; AlloMap to monitor
cardiac transplant patients for early immune rejection; and
Corus CAD to screen patients with symptoms suggestive of
myocardial ischemia in the clinic or emergency ward.
A widely reported failure of a set of highly touted omics-
based tests to direct the choice of the most effective cancer
chemotherapy agent for individual patients led to the request
by the National Cancer Institute and Duke University for
the Institute of Medicine to review this emerging field and
provide guidance on best practices, or “how to do it right” [3].
This guidance will be important for proteomics-based
biomarker test development, the subject of this special is-
sue. The IOM report clarifies the responsibilities of all the
investigators/co-authors, as well as of institutional review
bodies, funding agencies, journal editors and reviewers, and
the Food and Drug Administration (FDA) regulatory process.
Figure 2 lays out the three-phase process for omics-based
tests, with development and validation of the test in the first
two phases (first stage) and evaluation of the clinical utility
in a third phase (second stage). There is a bright line to be
passed before entering the assessment of clinical utility (sec-
ond stage).
3.1 Discovery phase
The product of the discovery phase is a fully described labora-
tory assay and a fully described, locked-down computational
procedure; before validation, it is important to confirm the
initial findings with an independent set of samples in the
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Figure 2. Omics-based test development
process, in three phases: discovery and con-
firmation, test validation in a clinical labo-
ratory, and evaluation for clinical utility and
clinical use. Source: [3] p.6.
same laboratory with the same staff and the same technology
platform. A common error in the discovery phase is tomingle
the “training set” of samples and the “test set of samples,” or
to combine the two after initial separate analysis, hoping to
enhance the AUC (area under the curve in a plot of specificity
vs. sensitivity). Such mingling should never be done. It is an
inexcusable error to know which samples are from patients
and which from controls, breaking the “blinded status” of the
analysis.
For a long time, it was standard practice in research to
repeat an experiment before rushing to publish or license;
now it is too often the case that a quite preliminary discovery
phase result is published without replication. In some cases,
there is a scheme for this preliminary result to be “handed off”
to a different lab for validation, as in the NCI Early Detection
Research Network. I highly recommend the IOM guidance
that the original laboratory should perform a confirmation
step before the test proceeds for analytical validation.
3.2 Test validation phase
The test validation phase moves the in vitro multianalyte as-
say from the research lab to a CLIA-certified (where CLIA
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is Clinical Laboratory Improvement Amendments) clinical
pathology laboratory for high throughput, rigorous calibra-
tion and quality assurance, and standardized practice. One
must note that CLIA certifies the laboratory, not the specific
test. Often the technology platform for the multianalyte test
is changed, for example, from MS to ELISA. This change
requires a full repeat cycle of the discovery phase training
and test set analyses with independent blinded specimens
after the new assay and the new computational procedures
are locked-down. Moreover, it is important that the specimen
sources and preanalytical procedures be matched to the cir-
cumstances expected with the intended clinical use of the
test. The IOM report insists that the assay details and the
algorithm and code for the classifier be made public.
It is wise to seek advice from the FDA at this stage and
to determine whether the test development will lead to a
submission to FDA for risk-based review and approval of the
test as an in vitro diagnostic multianalyte assay or the test will
be made available without FDA approval in a single reference
lab as a lab-directed test.
3.3 Evaluation for clinical utility
The evaluation for clinical utility has three potential pathways,
which may be alternatives or may be sequential, depending
on the intended use. All of these studies utilize patient spec-
imens or involve patients directly, so full human subjects
review by the Institutional Review Board (IRB) and Clinical
Protocol Review Committees must be performed and well
documented. Clinical trials must be recorded with detailed
protocols in www.clinicaltrials.gov. Any potential conflicts
of financial interest must be disclosed to the appropriate
institutional office and to the IRB for inclusion in the
informed consent.
It is highly desirable to seek FDA guidance before un-
dertaking these studies, as noted even for the test validation
phase; for the third of these clinical validation pathways, a fil-
ing for an investigational device exemption (IDE) is required.
As shown in Fig. 2, the first pathway utilizes archived
specimens from an already-completed randomized clinical
trial, if such specimens and trial results are available. This
prospective–retrospective study design, originally proposed
by Simon et al. [5], is an efficient way to evaluate the potential
usefulness of the test without putting any patients at risk.
Moreover, there is no multiyear wait to see the survival re-
sults of the alternative treatments for a prospective study of
randomly assigned patient groups.
The second pathway is a prospective assessment of the
predictive test with random assignment of patients; the test
results have no influence on the therapy given the patients.
Afterward, the test results permit comparison of treatment
outcomes with the alternative drugs.
The third pathway is the highest use of the predictive
omics test: the assignment of patients to specific alternative
therapies based on the prestudy results of the test. This path-
way requires the risk-based FDA IDE review; the developer
still has the option of a laboratory-developed test or an FDA
approval.
In the Duke case, the microarray-based molecular signa-
ture tests still under development [6] were used prematurely
to determine which drug specific patients with lung cancers
or breast cancers would receive in three separate clinical trials
launched in 2007. The principal investigator, lead author, and
11 and 15 co-authors, respectively, on the two papers failed
to recognize the incomplete and error-ridden nature of the
published results and chose not to utilize specific criticisms
from bioinformaticians at MDAnderson Cancer Center [7] to
improve the analyses before launching the three clinical trials
and also two companies to perform the laboratory assays and
the bioinformatics analyses. Documents prepared by Duke
for the IOM Committee review and Appendix B of the IOM
report lay out the details and timeline.
3.4 OVA1: A proteomics-based test with FDA
clearance for a narrow intended use
The following section is a truncated version of the case study
in Appendix A of the IOM report, pp. 209–213 [3]. In Septem-
ber 2009, the FDA cleared OVA1 (Vermillion) as the first in
vitro diagnostic multivariate index assay [8, 9]. It is the only
proteomics-based test marketed for clinical use, although its
clinical version is a multianalyte immunoassay. OVA1 is ap-
proved to help identify potential cases of ovarian cancer and
guide surgical treatment. OVA1 is the result of collaborative
efforts between Johns Hopkins University researchers led by
Zhen Zhang andDaniel Chan and scientists at Vermillion in-
cluding Eric Fung. The intended use of OVA1 is narrowly cir-
cumscribed; it is not a screening or a diagnostic test; rather it
is intended to guide treatment decisions by “[helping] patients
and health care professionals decide what type of surgery
should be done and bywhom” [9]. OVA1 is used in caseswhen
a patient has an adnexal pelvic mass that is already known
to require surgery. It measures serum levels of five plasma
proteins—CA 125 II, transthyretin (prealbumin), apolipopro-
teinA1, beta 2microglobulin, and transferrin—which change
in association with ovarian cancers. The biomarkers included
in the OVA1 panel (not including CA 125) were discovered
through multicenter proteomic studies [10]. A proprietary al-
gorithm produces a single numerical score between 0 and
10 that indicates the likelihood that a pelvic mass is benign
or malignant. A high OVA1 score identifies patients who are
likely to benefit from referral to a gynecological oncologist,
rather than a general surgeon, for surgery.
Fung recounted his experiences defining the OVA1 as-
say methodology and the process of obtaining FDA clearance
instead of opening a CLIA-certified laboratory without FDA
clearance of the specific test [11]. Investigators met FDA be-
fore starting clinical trials, during clinical trials, and during
the submission process. The FDAhelped in framing the test’s
intended use and the structure of the clinical trials necessary
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to evaluate clinical validity. The investigators initially sought
to develop the final algorithm using the SELDI-MS platform
that was used to identify the chosen markers. However, they
encountered difficulties with the analytic performance of the
SELDI methodology (not unlike those issues confronted by
Petricoin and Liotta earlier with OVACHECK [3]). They con-
cluded that the SELDI platform did not perform reproducibly
enough for routine clinical use. The researchers proceeded to
develop immunoassays for the markers that did not already
have such assays available. The panel was optimized through
several additional clinical trials. An earlier critical decision
was to give up on the goal of screening asymptomatic women
for ovarian cancers; simulation models demonstrated that
even a highly specific test would result in a very low positive
predictive value due to a highmultiple of false-positive results
to true positives [12].
In June 2008, the authors submitted their data to the
FDA. Subsequently, the investigators modified the intended
use and addressed clinical and analytical questions as a
result of discussions with regulatory scientists. One impor-
tant decision was to generate different cutoff values for pre-
menopausal and postmenopausal women. Data related to as-
say performance and clinical utility were presented at the
2010 AACR meeting.
Zhang and Chan [13] described critical issues relevant to
proteomic-based biomarker discovery and validation, includ-
ing the inherent complexity of the clinical sample proteome,
biological and preanalytical variability, and analytical validity.
Practical suggestions for minimizing the effect of potential
biases included defining a clear clinical utility from the out-
set, incorporating multicenter study design, employing ana-
lytical randomization, and paying close attention to the fac-
tors that contribute to false discovery and model overfitting.
Later they shared their insights from the OVA1 development
process in a 2010 “lessons learned” commentary [8]. They
described three main bridges critical to bringing research-
based biomarker discovery to the level of clinical diagnostics:
(i) generation of sufficient and “portable” evidence during
preliminary validation studies to support expansion into
larger scale validation studies, (ii) careful definition of clin-
ical utility goals that balance broad applicability with feasi-
bility in order to execute clinical trials that will fulfill reg-
ulatory requirements, and (iii) selection of assays with the
proper analytical performance necessary for clinical use. A
space diagram comparing OVA1 and a fictitious screening
assay illustrates the tradeoffs between narrowly defined tests
(OVA1) and broad-based screening tests, highlighting the
consequences of false negatives and false positives and re-
lated factors. The authors emphasized the fact that a research
assay does not necessarily translate into a clinical assay, re-
lating their switch to an immunoassay format.
The “test” marketed by Quest Diagnostics comprises Ova-
Calc Software as well as the instruments, assays, and reagents
recommended by Vermillion and sold separately from the
OvaCalc software. As of 2011, OVA1 had its CE Mark in
the European Union and was covered by Medicare, 22 Blue
Cross Blue Shield plans, and other private health plans in
the United States. On May 15, 2013, Vermilion announced
an initiative to migrate OVA1 to a state-of-the-art clinical test-
ing platform commonly available around the world by end
of 2014.
4 The roles of responsible parties in the
development and clinical use of
omics-based predictive tests
Here I provide highlights of the recommendations from the
IOM report [3].
4.1 The principal investigator and research team
There can be no ambiguity that the principal investigator of
the discovery laboratory is the person most responsible for
the culture of the laboratory, the performance of all members
of the laboratory, and transparent and respectful interactions
with the institutional oversight groups, ranging from depart-
ment chairs and deans, to Human Subjects IRBs, Clinical
Trials Scientific Protocol Review Committees, and Conflict of
Interest Review and Management processes. Potential con-
flicts of interest must be disclosed to the IRB and potential
trial participants. If licensing or company launches are con-
templated, the principal investigator/company founder and
his or her collaborators must make full disclosures to the
Office of Technology Transfer.
It should be obvious that all co-authors on publications
and co-investigators on grant proposals and clinical trials pro-
tocols must learn enough about the full project and interact
sufficiently to have confidence that all required scientific steps
and oversight have been completed responsibly. If there are
criticisms about any aspect of the work, either internally or
externally from journal or funding agency reviewers or col-
leagues, all co-authors should be informed and contribute to
the responses. As noted in theDukeCase Study [3], all authors
were held accountable when numerous publications were re-
tracted (in August 2011, Duke reported 14 fully retracted and
13 partially retracted).
4.2 The research institutions
In 2002, the National Research Council and Institute of
Medicine published “Integrity in Scientific Research: Creat-
ing an Environment that Promotes Responsible Conduct [14].
They listed the following practices: “providing leadership in
support of responsible conduct of research; encouraging re-
spect for everyone involved in research; promoting produc-
tive interactions between trainees and mentors; advocating
adherence to the rules regarding all aspects of the conduct
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of research anticipating, revealing, and managing individual
and institutional conflicts of interest; arranging timely and
thorough inquiries and investigations of allegations of sci-
entific misconduct and applying appropriate administrative
sanctions; offering education pertaining to integrity in the
conduct of research; and monitoring and evaluating the in-
stitutional environment supporting integrity in the conduct
of research and using this knowledge for continuous quality
improvement.”
The IOM 2012 report [3] stated that any institution not ca-
pable of managing these complex responsibilities should not
be conducting this kind of research. A gap in the institutional
procedures appears to be the requirement for an allegation
of misconduct before the institution launches an inquiry, let
alone an investigation; as Duke leaders testified to the Com-
mittee [3], “therewere numerousmissed signals” aboutmajor
problems in the conduct of research and oversight of research
by the Nevins laboratory.
The IOM recommended that there be a specific IRBmem-
ber responsible for considering IDE and IND requirements;
an institutional official responsible for comprehensive and
timely documentation, disclosure, and management of fi-
nancial and nonfinancial conflicts of interest; an institutional
official responsible for establishing and managing a safe sys-
tem for preventing, reporting, and adjudicating lapses in
scientific integrity and risks to patient safety; and an institu-
tional official responsible for responding to inquiries or crit-
icisms about the science being conducted at the institution,
including inquiries from journals. Institutions also should be
sensitive to the vulnerability of biostatisticians and bioinfor-
maticians employed on grants to demands from powerful
principal investigators to find a method that supports the
desired findings.
4.3 Funding agencies, staff, and reviewers
Funders can and should play a leadership role in support-
ing a culture of integrity and transparency in science, while
providing the resources and guidance to accelerate discovery,
translation, and clinical applications. Funding of indepen-
dent validation of omics-based tests may be justified by the
need to make better decisions about advancing biomarker
tests through the development path (Fig. 2). The committee
recommended that funders require investigators to make all
data, metadata, prespecified analysis plans, computer code,
and fully specified computational procedures publicly avail-
able and readily interpretable at the time of publication
or the end of funding. Funders also were advised to sup-
port independent repositories for such data and test valida-
tion in CLIA-certified labs. They were encouraged to estab-
lish lines of communication with other funders that could
be useful when serious problems arise in interdependent
research.
4.4 Journals and journal editors
There is a fundamental problem in the publication business.
With extreme emphasis on gettingmanuscripts into themost
prestigious journals with high impact factors, the pressure to
producemanuscripts with nowarts and no acknowledgement
of complications in the findings is distorting the quality and, it
seems, the replicability of reported findings. Editors point out
that the responsibility for articles rests with the authors, not
the unpaid reviewers or editorial staff, especially for articles
with complex computational aspects or big datasets.
The IOM Committee recommended that journal editors
require authors who submit manuscripts describing clinical
evaluations of omics-based tests to register all clinical trials
at www.clinicaltrials.gov or an equivalent registry; to make
the data, metadata, analysis plans, code, and fully specified
computational procedures for a biomarker candidate pub-
licly available in a standard format (e.g. dbGAP); to provide
the journal with the sections of the research protocol relevant
to the manuscript; to identify each author’s role in the vari-
ous phases of the manuscript; to require the lead and senior
authors to attest to the integrity of the study and have the co-
authors confirm shared responsibility; and to use checklists
for authors to document compliance with appropriate guide-
lines (e.g. CONSORT, REMARK). Editorswere also advised to
develop better mechanisms to resolve possible serious errors
in publications and to alert the institutional leadership and
all authors when a serious question of accuracy or integrity
has been raised.
4.5 The FDA
The FDA has established increasingly useful lines of com-
munication with academic and industry groups developing
multianalyte tests, other devices, and drugs. The Committee
recommended that FDA enable investigators and institutions
to have a clearer understanding of regulatory responsibilities
by completing and finalizing the long-gestating risk-based
guidance for omics-based tests. Such a guidance is appar-
ently under final review currently at the Office of Manage-
ment and Budget. It should clarify the criteria or pros-and-
cons for bringing an omics-based test to FDA for review and
the same for laboratory-developed tests. It might help IRBs,
protocol review committees, institutional leaders, and inves-
tigators if FDA communicated the IDE requirements for use
of omics-based tests in clinical trials.
4.6 Implications for international drug development
For many years, there has been a concerted effort toward
harmonization of drug development testing and registration
policies and guidance involving the United States, Europe,
and Japan. As described in a Workshop Summary from the
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Institute of Medicine of the US National Academy of Sci-
ences [15], the International Conference on Harmonization
is sponsored by the drug regulatory agencies and pharmaceu-
tical manufacturers of Europe, Japan, and the United States,
with the World Health Organization, Health Canada, the
European Free TradeAssociation, and the Federation of Phar-
maceutical Manufacturers and Associations as observers. All
of these agencies are striving to catch up with the dramatic
developments in genomics, proteomics, metabolomics, and
other “omics” fields to evaluate diagnostic tests, aswell as new
drugs. As other countries become major producers of phar-
maceuticals, the impetus for harmonization and the need for
molecular biology expertise will continue to grow.
European and Japanese developers and marketers of
high-profile omics-based clinical tests are or should be well
aware of FDA requirements, given their desire to market the
test(s) in the United States, just as US companies must learn
the policies and requirements for these other regions of the
world.
5 Outlook
The progress toward “precision medicine” [1] or “predictive,
prospective, preventive, and participatory medicine” [16] is
accelerating. Multiple highly targeted drugs with compan-
ion diagnostic tests are entering clinical trials and clinical
practice. The most prominent examples are (i) Gleevec (ima-
tinib) for Philadelphia chromosome-positive chronic myel-
ogenous leukemia with the 9;22 translocation that pro-
duces the BCR-ABL kinase; (ii) Herceptin (trastuzumab)
for Her2/neu (ERRB2) amplified breast cancers; (iii) Er-
bitux and Vectibix (cetuximab, panitumamab) for EGF re-
ceptors in colorectal cancers; and (iv) Xalkori (crizotinib) for
EML-ALK fusion gene/protein in non-small cell lung can-
cers. In these cases, we have drugs that work for the specific
carcinogenic mechanism; with reliable tests, we can match
the patients to the specifically indicated drug, with excellent
results. Gleevec also works on the same target found in rare
gastrointestinal stromal tumors andHerceptinworks on non-
breast cancers that have the corresponding ERBB2-amplified
mechanism (gastric, colorectal, and rare lung cancers).
At the University of Michigan, the Center for Transla-
tional Pathology led by Arul Chinnaiyan has established
the MI-Onco-Seq clinical laboratory service to perform
RNA-sequencing on tumor specimens to match patients to
available therapies and guide new research for much needed
additional agents [17, 18]. We can expect progressive use of
multianalyte proteomics based tests in the coming years.
Companion diagnostics for these targeted therapies may
be based on individual mutations or on multianalyte assays.
More broadly, however, cancer biomarker test development
and adoption into clinical use has lagged far behind advances
in therapy. Hayes et al. [19] call this record a “vicious cy-
cle” of undervaluation resulting from inconsistent regulatory
standards and unreliable reimbursement, as well as insuffi-
cient investment in research and development, lax scrutiny of
biomarker manuscripts by journals, and inadequate evidence
of analytical validity and clinical utility. Co-authors Daniel
Hayes, Debra Leonard, and David Ronsohoff were members
of the IOM Committee on omics-based predictive tests. They
recommend changes in regulation, reimbursement, invest-
ment, peer review, and guidelines that require the participa-
tion of all the stakeholders. They endorse the IOM frame-
work for development of new omics-based biomarker tests
(above). All of these recommendations apply to development
of proteomics-based multianalyte tests. They cite an estimate
that diagnostics account for <2% of total healthcare spend-
ing, but influence 60% of clinical decision-making.
The promise of personalized medicine rests on achieving
these objectives, creating a virtuous cycle in which tumor
biomarkers are properly valued by all stakeholders.
The author has declared no conflict of interest.
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